Predictive Tumor Biomarkers for EGFR Inhibitors - Wikidata - wikimedia - TriplyDB

Predictive Tumor Biomarkers for EGFR Inhibitors

Predictive Tumor Biomarkers for EGFR Inhibitors

http://www.wikidata.org/entity/Q57896476

about

Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study.

P2860

Q40929491-9353A047-9858-4F12-81D6-0CF937BA7E8B

P2860

Predictive Tumor Biomarkers for EGFR Inhibitors

http://www.wikidata.org/entity/Q57896476

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у квітні 2014

@uk

name

Predictive Tumor Biomarkers for EGFR Inhibitors

@en

Predictive Tumor Biomarkers for EGFR Inhibitors

@nl

type

label

Predictive Tumor Biomarkers for EGFR Inhibitors

@en

Predictive Tumor Biomarkers for EGFR Inhibitors

@nl

prefLabel

Predictive Tumor Biomarkers for EGFR Inhibitors

@en

Predictive Tumor Biomarkers for EGFR Inhibitors

@nl

P1476

Q57896476-5EB3B2B1-0DEB-4CF1-9DCA-0D3C7656DE59

P2093

Q57896476-B4E385B2-1276-4829-AB83-F9A93B7E2412

P2860

Q57896476-00B94F10-C396-468F-B52D-3C57463085F3

Q57896476-0186CCE7-6F13-468A-B4F6-58D3961AC38B

Q57896476-02C7F52F-0A47-420A-B4AF-68C75783D068

Q57896476-031AC632-F889-4DB6-98F6-317BBA088319

Q57896476-06533C3F-27AC-4061-8091-B31BDBF291D4

Q57896476-06B30C3F-6D71-4AF1-8D07-58EB26204C93

Q57896476-084B0AE6-2DF1-4DA6-9A51-7F00C7DC8E5D

Q57896476-084F5424-D271-4201-ADB0-39550D3CE4EF

Q57896476-0AB5A71C-9F90-4DA1-BC3E-F8437D5CE739

Q57896476-0B8FCC55-CEA0-4607-8B93-7B9BB777F898

P304

Q57896476-95A053BB-4A4E-4E6D-90CA-BC6216962973

P31

Q57896476-CE54B0E7-6533-4CD2-A7B4-9D6673148D18

P356

Q57896476-7C19D22F-2F1E-44E0-A45B-000270B20F46

P50

Q57896476-8E85A1B2-6511-481C-B220-018A0A580886

Q57896476-9D862DCD-2086-4114-B419-51C962198C54

P577

Q57896476-EB53CD6A-2794-486E-AE0F-85FF02580345

P921

Q57896476-39FD3AB3-6F5F-46F2-B558-9E3EF26D9411

P356

9781118468791.CH28

P1476

Predictive Tumor Biomarkers for EGFR Inhibitors

@en

P2093

Lucia Kim

http://www.w3.org/2001/XMLSchema#string

P2860

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor

P304

435-453

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/9781118468791.CH28

http://www.w3.org/2001/XMLSchema#string

P50

Ming-Sound Tsao

P577

2014-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P921